Research
Recombinant λ-phage nanobioparticles for tumor therapy in mice models
-
* Corresponding author: Hoorieh Soleimanjahi soleim_h@modares.ac.ir
1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111 Iran
2 Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, 14115-175 Iran
3 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111 Iran
4 Shefa Neuroscience Research Centre, Tehran, Iran
5 Hepatitis and AIDS Department, Pasteur Institute, Tehran, Iran
6 Faculty of Medicine, Golestan University of Medical Sciences and Health Care, Gorgan, Iran
Genetic Vaccines and Therapy 2010, 8:3 doi:10.1186/1479-0556-8-3
Published: 12 May 2010Abstract
Lambda phages have considerable potential as gene delivery vehicles due to their genetic tractability, low cost, safety and physical characteristics in comparison to other nanocarriers and gene porters. Little is known concerning lambda phage-mediated gene transfer and expression in mammalian hosts. We therefore performed experiments to evaluate lambda-ZAP bacteriophage-mediated gene transfer and expression in vitro. For this purpose, we constructed recombinant λ-phage nanobioparticles containing a mammalian expression cassette encoding enhanced green fluorescent protein (EGFP) and E7 gene of human papillomavirus type 16 (λ-HPV-16 E7) using Lambda ZAP- CMV XR vector. Four cell lines (COS-7, CHO, TC-1 and HEK-239) were transduced with the nanobioparticles. We also characterized the therapeutic anti-tumor effects of the recombinant λ-HPV-16 E7 phage in C57BL/6 tumor mice model as a cancer vaccine. Obtained results showed that delivery and expression of these genes in fibroblastic cells (COS-7 and CHO) are more efficient than epithelial cells (TC-1 and HEK-239) using these nanobioparticles. Despite the same phage M.O.I entry, the internalizing titers of COS-7 and CHO cells were more than TC-1 and HEK-293 cells, respectively. Mice vaccinated with λ-HPV-16 E7 are able to generate potent therapeutic antitumor effects against challenge with E7- expressing tumor cell line, TC-1 compared to group treated with the wild phage. The results demonstrated that the recombinant λ-phages, due to their capabilities in transducing mammalian cells, can also be considered in design and construction of novel and safe phage-based nanomedicines.